Metraipolis › archive › dc_84c8385dfe7b
Real-World Renal and Metabolic Outcomes of SGLT-2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus — Europe PMC PMID:42941589
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42941589
- DOI
- 10.3390/jcm15208076
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T01:38:19.150Z
- SHA-256 of the archived text
86ae10fd20e71db642d9e447a4b9102c74aa622c2948739f576ce9ed173c3551- Stable URL of this page
https://metraipolis.com/documento/dc_84c8385dfe7b
How to cite
Real-World Renal and Metabolic Outcomes of SGLT-2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus — Europe PMC PMID:42941589 — Europe PMC (en), https://europepmc.org/article/MED/42941589 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_84c8385dfe7b (Metraipolis archive dc_84c8385dfe7b, sha256 86ae10fd20e71db642d9e447a4b9102c74aa622c2948739f576ce9ed173c3551)
BibTeX
@misc{dc84c8385dfe7b,
title = {Real-World Renal and Metabolic Outcomes of SGLT-2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus — Europe PMC PMID:42941589},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42941589},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_84c8385dfe7b; sha256 86ae10fd20e71db642d9e447a4b9102c74aa622c2948739f576ce9ed173c3551},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42941589. Agents can read the archived copy with the MCP tool read_document.